Atlas FDA

NMP22 BLADDERCHEK TEST

FDA premarket approval P940035/S009 · decided 2013-04-02

Approval details

PMA number
P940035
Supplement
S009
Supplement type
30-Day Notice
Supplement reason
Process Change - Manufacturer/Sterilizer/Packager/Supplier
Trade name
NMP22 BLADDERCHEK TEST
Generic name
System, test, tumor marker, for detection of bladder cancer
Applicant
Abbott Diagnostics Scarborough, Inc.
Date received
2013-03-18
Decision date
2013-04-02
Days to decision
15 days
Decision code
OK30
Product code
NAH
Advisory committee
Immunology
Expedited review
No
Location
Scarborough, ME
Statement
INCREASE THE MANUFACTURING EFFICIENCY OF THE ASSEMBLED CASSETTE BY MODIFYING THE ASSEMBLY METHOD USED IN THE MANUFACTURE OF NMP22 BLADDERCHEK FROM ASSEMBLED AND POUCHED MANUALLY BY HAND BY OPERATORS, TO BE ASSEMBLED BY VALIDATED AUTOMATED EQUIPMENT.

Class III intelligence, same tools

PMAs share the API, exports and alerts with 510(k) data - watch an applicant and hear about every approval.

510(k) clearances by this applicant

RecordFirmDate
BinaxNOW COVID-19 Ag Card (K250273)Abbott Diagnostics Scarborough, Inc.2025-06-13
BinaxNOW™ COVID-19 Antigen Self Test (K243518)Abbott Diagnostics Scarborough, Inc.2025-02-11
ID NOW Influenza A & B 2 (K232775)Abbott Diagnostics Scarborough, Inc.2023-10-10
ID NOW COVID-19 2.0 (K221925)Abbott Diagnostics Scarborough, Inc.2023-08-10
ID Now Instrument, ID Now Influenza A & B 2, ID NOW Strep A 2 (K220801)Abbott Diagnostics Scarborough, Inc.2022-06-24
ID NOW Influenza A & B 2 (K191534)Abbott Diagnostics Scarborough, Inc.2019-07-11